These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

594 related articles for article (PubMed ID: 30733618)

  • 1. Dementia in Down syndrome: unique insights for Alzheimer disease research.
    Lott IT; Head E
    Nat Rev Neurol; 2019 Mar; 15(3):135-147. PubMed ID: 30733618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Down syndrome and Alzheimer's disease: common molecular traits beyond the amyloid precursor protein.
    Gomez W; Morales R; Maracaja-Coutinho V; Parra V; Nassif M
    Aging (Albany NY); 2020 Jan; 12(1):1011-1033. PubMed ID: 31918411
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Down Syndrome, Partial Trisomy 21, and Absence of Alzheimer's Disease: The Role of APP.
    Doran E; Keator D; Head E; Phelan MJ; Kim R; Totoiu M; Barrio JR; Small GW; Potkin SG; Lott IT
    J Alzheimers Dis; 2017; 56(2):459-470. PubMed ID: 27983553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Elucidating Pathogenic Mechanisms of Early-onset Alzheimer's Disease in Down Syndrome Patients].
    Asai M; Kawakubo T; Mori R; Iwata N
    Yakugaku Zasshi; 2017; 137(7):801-805. PubMed ID: 28674290
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Neuropathological role of PI3K/Akt/mTOR axis in Down syndrome brain.
    Perluigi M; Pupo G; Tramutola A; Cini C; Coccia R; Barone E; Head E; Butterfield DA; Di Domenico F
    Biochim Biophys Acta; 2014 Jul; 1842(7):1144-53. PubMed ID: 24735980
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PET measurement of longitudinal amyloid load identifies the earliest stages of amyloid-beta accumulation during Alzheimer's disease progression in Down syndrome.
    Zammit MD; Tudorascu DL; Laymon CM; Hartley SL; Zaman SH; Ances BM; Johnson SC; Stone CK; Mathis CA; Klunk WE; Cohen AD; Handen BL; Christian BT
    Neuroimage; 2021 Mar; 228():117728. PubMed ID: 33421595
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Aging in Down Syndrome and the Development of Alzheimer's Disease Neuropathology.
    Head E; Lott IT; Wilcock DM; Lemere CA
    Curr Alzheimer Res; 2016; 13(1):18-29. PubMed ID: 26651341
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.
    Cenini G; Dowling AL; Beckett TL; Barone E; Mancuso C; Murphy MP; Levine H; Lott IT; Schmitt FA; Butterfield DA; Head E
    Biochim Biophys Acta; 2012 Feb; 1822(2):130-8. PubMed ID: 22009041
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Alzheimer-Related Cerebrovascular Disease in Down Syndrome.
    Lao PJ; Gutierrez J; Keator D; Rizvi B; Banerjee A; Igwe KC; Laing KK; Sathishkumar M; Moni F; Andrews H; Krinsky-McHale S; Head E; Lee JH; Lai F; Yassa MA; Rosas HD; Silverman W; Lott IT; Schupf N; Brickman AM
    Ann Neurol; 2020 Dec; 88(6):1165-1177. PubMed ID: 32944999
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible compensatory events in adult Down syndrome brain prior to the development of Alzheimer disease neuropathology: targets for nonpharmacological intervention.
    Head E; Lott IT; Patterson D; Doran E; Haier RJ
    J Alzheimers Dis; 2007 Mar; 11(1):61-76. PubMed ID: 17361036
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phosphorylated Aβ peptides in human Down syndrome brain and different Alzheimer's-like mouse models.
    Kumar S; Lemere CA; Walter J
    Acta Neuropathol Commun; 2020 Jul; 8(1):118. PubMed ID: 32727580
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alzheimer's disease amyloid-beta links lens and brain pathology in Down syndrome.
    Moncaster JA; Pineda R; Moir RD; Lu S; Burton MA; Ghosh JG; Ericsson M; Soscia SJ; Mocofanescu A; Folkerth RD; Robb RM; Kuszak JR; Clark JI; Tanzi RE; Hunter DG; Goldstein LE
    PLoS One; 2010 May; 5(5):e10659. PubMed ID: 20502642
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of monomeric and soluble aggregated Aβ in Down's syndrome and Alzheimer's disease brains.
    Gkanatsiou E; Sahlin C; Portelius E; Johannesson M; Söderberg L; Fälting J; Basun H; Möller C; Odergren T; Zetterberg H; Blennow K; Lannfelt L; Brinkmalm G
    Neurosci Lett; 2021 May; 754():135894. PubMed ID: 33848613
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Dysfunction of autophagy and endosomal-lysosomal pathways: Roles in pathogenesis of Down syndrome and Alzheimer's Disease.
    Colacurcio DJ; Pensalfini A; Jiang Y; Nixon RA
    Free Radic Biol Med; 2018 Jan; 114():40-51. PubMed ID: 28988799
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Genetic Mapping of APP and Amyloid-β Biology Modulation by Trisomy 21.
    Mumford P; Tosh J; Anderle S; Gkanatsiou Wikberg E; Lau G; Noy S; Cleverley K; Saito T; Saido TC; Yu E; Brinkmalm G; Portelius E; Blennow K; Zetterberg H; Tybulewicz V; Fisher EMC; Wiseman FK
    J Neurosci; 2022 Aug; 42(33):6453-6468. PubMed ID: 35835549
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting increased levels of APP in Down syndrome: Posiphen-mediated reductions in APP and its products reverse endosomal phenotypes in the Ts65Dn mouse model.
    Chen XQ; Salehi A; Pearn ML; Overk C; Nguyen PD; Kleschevnikov AM; Maccecchini M; Mobley WC
    Alzheimers Dement; 2021 Feb; 17(2):271-292. PubMed ID: 32975365
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Patterns and severity of vascular amyloid in Alzheimer's disease associated with duplications and missense mutations in APP gene, Down syndrome and sporadic Alzheimer's disease.
    Mann DMA; Davidson YS; Robinson AC; Allen N; Hashimoto T; Richardson A; Jones M; Snowden JS; Pendleton N; Potier MC; Laquerrière A; Prasher V; Iwatsubo T; Strydom A
    Acta Neuropathol; 2018 Oct; 136(4):569-587. PubMed ID: 29770843
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Alzheimer's Disease in Down Syndrome: Progress in the Design and Conduct of Drug Prevention Trials.
    Rafii MS
    CNS Drugs; 2020 Aug; 34(8):785-794. PubMed ID: 32506291
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical aspects and biomarkers of Alzheimer's disease in Down syndrome.
    Zis P; Strydom A
    Free Radic Biol Med; 2018 Jan; 114():3-9. PubMed ID: 28870521
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequence of deposition of heterogeneous amyloid beta-peptides and APO E in Down syndrome: implications for initial events in amyloid plaque formation.
    Lemere CA; Blusztajn JK; Yamaguchi H; Wisniewski T; Saido TC; Selkoe DJ
    Neurobiol Dis; 1996 Feb; 3(1):16-32. PubMed ID: 9173910
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 30.